Canadian Rheumatology in Immuno-oncology (CanRIO)

CanRIO is a network of Canadian rheumatologists and researchers with expertise in rheumatic immune related adverse events #arthritis #immunotherapy

[Canadian Rheumatology in Immuno-oncology (CanRIO) @CanRIO_Tweets]

New article published today in ACR Open Rheumatology from CanRIO showing ICI-inflammatory arthritis frequently persists after ICI discontinuation but is associated with improved progression free survival. https://t.co/fAifuU9t0w

[Janet Pope @Janetbirdope]

#ClinicalPearl

#Myositis with #immune #checkpoint #inhibitors #ICI

May have concomitant #myasthenia #gravis

#CK May not be really ⬆️

⁦@jeffsparks⁩ presenting ⁦@ORAexec⁩

#ORA24

[Janet Pope @Janetbirdope]

#Immune #checkpoint #inhibitors in #malignancy

✅Can affect any organ

✅ Rash, colitis. Endocrine, Rheumatic are frequent

#ClinicalPearl

⁦@ORAexec⁩ #ORA24

presented by ⁦@jeffsparks⁩

[Canadian Rheumatology in Immuno-oncology (CanRIO) @CanRIO_Tweets]

Congratulations to Dr Marie Hudson for being awarded an Arthritis Society of Canada grant to study the mechanisms underlying rheumatic immune related adverse events! https://t.co/VP5mT3BmR3

[Canadian Rheumatology in Immuno-oncology (CanRIO) @CanRIO_Tweets]

Congrats to CanRIO member Dr. May Choi for her “Top 40 under 40” recognition! https://t.co/NShjUKMStL

[Canadian Rheumatology in Immuno-oncology (CanRIO) @CanRIO_Tweets]

Congrats to Dr. Shahin Jamal and Dr. Tom Appleton (@appletonlab) on receiving a 2023 CIORA grant for their study on Early Adalimumab Induction for Treatment of Steroid-Dependent CPI Associated Inflammatory Arthritis: A Pragmatic RCT!
@CRASCRRheum #CanRIO #CIORA #immunotherapy

[Canadian Rheumatology in Immuno-oncology (CanRIO) @CanRIO_Tweets]

We agree, check it out! ☺️

[Janet Pope @Janetbirdope]

Congratulations 🎉 Great HCP and patient info and education at the Canadian Research Group of Rheumatology in Immunology-Oncology #CanRIO Check out the website https://t.co/TvhMgdkzyh @Canrio_tweets

[David Liew @drdavidliew]

Important from @cappelliMD @jhrheumatology irAE cohort on predictors of DMARD requirement in ICI-inflammatory arthritis, and persistent ICI-IA post-ICI cessation.

The better we can predict these patients, the more we can get the right therapy early
POS0951 #EULAR2023 @RheumNow

[NatRevRheumatol @NatRevRheumatol]

#NovemberIssue | Read about immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases in this #Review

https://t.co/1YuAKpzGwq

[Janet Pope @Janetbirdope]

Ongoing work to #classify #inflammatory #arthritis in Pts using #check #point #inhibitors. A 1st step to study the etiology of immune changes from these life prolonging medications #EULAR2023 @RheumNow

[Canadian Rheumatology in Immuno-oncology (CanRIO) @CanRIO_Tweets]

The conclusion: Patients with pre-existing RA receiving ICI have similar risk of mortality and severe ir-AE compared to those without RA. But do have more ir-AE in general manifesting as mild RA flare

[The Lancet Rheumatology @TheLancetRheum]

ICYMI, the inspiration for our May cover—Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study https://t.co/ttjnfexiCc

[Canadian Rheumatology in Immuno-oncology (CanRIO) @CanRIO_Tweets]

@Lauren_King_ @UofTDoMChair @NoahIvers @LorraineLipsc17 Congratulations Lauren 👏👏

[The Lancet Rheumatology @TheLancetRheum]

@Deepakarao @jeffsparks Reconciling immunotherapy and autoimmunity: not for the faint of heart

Linked Comment by Carrie Ye @UAlberta_DoM https://t.co/ClIEOtlVma

[Canadian Rheumatology in Immuno-oncology (CanRIO) @CanRIO_Tweets]

Article published by our very own Dr. Carrie Ye (University of Alberta) in the @LancetRheum March 2023 discussing the challenges of autoimmunity in the setting of #immunotherapy:
https://t.co/ruZQ3TeDS0

[Canadian Rheumatology in Immuno-oncology (CanRIO) @CanRIO_Tweets]

Thank you to Dr. Ann Bass @lovetolearn27 for interesting discussion re: safety of DMARDs for Rh-irAE's at recent CanRIO International Case Rounds. Study published April 2023 shows higher likelihood of cancer progression with TNFi and IL-6Ri compared to MTX
https://t.co/CFhL89KiWl

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC position article and guidelines: Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology https://t.co/ZEXLoyAfRc @DrJNaidoo @JulieBrahmer @EladSharonMD @cappelliMD

[Canadian Rheumatology in Immuno-oncology (CanRIO) @CanRIO_Tweets]

Interested in rheumatic immune related adverse events (Rh ir-AE) in patients receiving cancer immunotherapy? Explore the CanRIO website for learning modules, patient resources, and up to date research: https://t.co/FEpDt1SINJ